CA3020815A1 - Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin - Google Patents

Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin Download PDF

Info

Publication number
CA3020815A1
CA3020815A1 CA3020815A CA3020815A CA3020815A1 CA 3020815 A1 CA3020815 A1 CA 3020815A1 CA 3020815 A CA3020815 A CA 3020815A CA 3020815 A CA3020815 A CA 3020815A CA 3020815 A1 CA3020815 A1 CA 3020815A1
Authority
CA
Canada
Prior art keywords
subject
rtx
administration
hypertension
epidural space
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3020815A
Other languages
English (en)
French (fr)
Inventor
Irving H. ZUCKER
Hanjun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska System
Original Assignee
University of Nebraska System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nebraska System filed Critical University of Nebraska System
Publication of CA3020815A1 publication Critical patent/CA3020815A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3020815A 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin Pending CA3020815A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322079P 2016-04-13 2016-04-13
US62/322,079 2016-04-13
PCT/US2017/027480 WO2017180907A1 (en) 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Publications (1)

Publication Number Publication Date
CA3020815A1 true CA3020815A1 (en) 2017-10-19

Family

ID=60039929

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3020815A Pending CA3020815A1 (en) 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Country Status (9)

Country Link
US (3) US20170296506A1 (https=)
EP (1) EP3442523A4 (https=)
JP (3) JP6980694B2 (https=)
KR (2) KR102395342B1 (https=)
CN (2) CN120114438A (https=)
AU (1) AU2017248665B2 (https=)
CA (1) CA3020815A1 (https=)
IL (2) IL298314B2 (https=)
WO (1) WO2017180907A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490745A (zh) 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
EP3914595A4 (en) 2019-01-22 2022-11-09 Sorrento Therapeutics, Inc. METHOD OF TREATMENT OF OSTEOARTHRITIS PAIN BY ADMINISTRATION OF RESINIFERATOXIN
CA3188689A1 (en) * 2020-08-11 2022-02-17 Alexis G. Nahama Treating pulmonary inflammatory disease by neural ablation
CA3219312A1 (en) * 2021-05-18 2022-11-24 Alexis Nahama Presurgical perineural administration of resiniferatoxin for reduction of post-operative pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
WO2007017764A2 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and muopioid agonist activity
RU2432950C2 (ru) * 2006-01-25 2011-11-10 Инсис Терапьютикс Инк. Подъязычный спрей на основе фентанила
US20100158973A1 (en) * 2006-03-13 2010-06-24 Hadasit Medical Research Services & Development Llimited Therapeutic uses of cannabidiol compounds
CN101522181A (zh) * 2006-10-04 2009-09-02 纽若科伊公司 诱导低体温药物在治疗局部缺血的应用
CN101951937A (zh) * 2007-12-21 2011-01-19 赫尔辛医疗股份公司 使用伊帕瑞林刺激胃肠系统动力的方法
WO2012045587A1 (en) * 2010-10-06 2012-04-12 Celltrend Gmbh A new method for diagnosing hypertension as well as cardiomyopathies
MY172557A (en) * 2013-09-17 2019-12-02 Vectus Biosystems Ltd Compositions for the treatment of hypertension and/or fibrosis
US9956166B2 (en) * 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Also Published As

Publication number Publication date
EP3442523A4 (en) 2019-12-04
EP3442523A1 (en) 2019-02-20
CN109562096A (zh) 2019-04-02
JP7341203B2 (ja) 2023-09-08
JP6980694B2 (ja) 2021-12-15
IL298314B1 (en) 2024-12-01
JP2019511536A (ja) 2019-04-25
IL298314B2 (en) 2025-04-01
IL262328A (en) 2018-11-29
AU2017248665B2 (en) 2023-01-05
WO2017180907A1 (en) 2017-10-19
JP2023155365A (ja) 2023-10-20
IL262328B (en) 2022-12-01
US20170296506A1 (en) 2017-10-19
US20250082605A1 (en) 2025-03-13
US20220000837A1 (en) 2022-01-06
CN120114438A (zh) 2025-06-10
KR20190029511A (ko) 2019-03-20
KR102508022B1 (ko) 2023-03-10
KR20220062667A (ko) 2022-05-17
AU2017248665A1 (en) 2018-11-08
KR102395342B1 (ko) 2022-05-10
IL298314A (en) 2023-01-01
IL262328B2 (en) 2023-04-01
JP2022001608A (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
US20250082605A1 (en) Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin
Chrysostomou et al. Perioperative use of dexmedetomidine is associated with decreased incidence of ventricular and supraventricular tachyarrhythmias after congenital cardiac operations
Tong et al. Liposomal bupivacaine and clinical outcomes
Benedetti et al. Control of postoperative pain by transcutaneous electrical nerve stimulation after thoracic operations
Choi et al. Combined low-dose spinal-epidural anesthesia versus single-shot spinal anesthesia for elective cesarean delivery
Agrawal et al. Effect of intrathecal midazolam bupivacaine combination on post operative analgesia
Miller et al. Implantation of the subcutaneous implantable cardioverter–defibrillator with truncal plane blocks
Krutsch et al. A case report of subcutaneous peripheral nerve stimulation for the treatment of axial back pain associated with postlaminectomy syndrome
Vossler et al. Intercostal nerve cryoablation for control of traumatic rib fracture pain: a case report
Dost et al. Pain management in minimally invasive cardiac surgery: a review of current clinical evidence
JP2620642B2 (ja) 麻薬性鎮痛剤とベンゾジアゼピンとを組み合わせて非経口投与した後に観察される平均血圧の低下を拮抗させるための医薬品
Banerjee et al. A comparative study between epidural butorphanol, nalbuphine, and fentanyl for post-operative analgesia in lower abdominal surgeries
Yakovlev et al. Treatment of chronic intractable atypical facial pain using peripheral subcutaneous field stimulation
Camci et al. Implantable cardioverter-defibrillator placement in patients with mild-to-moderate left ventricular dysfunction: hemodynamics and recovery profile with two different anesthetics used during deep sedation
Imamura et al. A case of coronary artery spasm during spinal anesthesia
Sakura et al. Using ultrasound guidance in peripheral nerve blocks
Saini et al. Anaesthetic Management of Major Abdominal Oncosurgery in a Patient With an Automated Implantable Cardioverter-Defibrillator (AICD): A Case Report
Staudt et al. Neuromodulation for Non-urologic Chronic Pain
Sudhakaran et al. A prospective study evaluating the effectiveness of epidural volume extension with normal saline in combined spinal epidural anesthesia for lower limb orthopedic surgeries using low dose intrathecal hyperbaric bupivacaine.
Pal et al. The efficacy of Clonidine added to Bupivacaine as compared with bupivacaine alone used in supraclavicular brachial plexus block for upper limb surgeries
Manzano et al. Severe Bradycardia after Topical Use of Papaverine during a Pons Cavernoma Surgery
Mahajan et al. THE ANALGESIC EFFICACY AND SAFETY OF EPIDURAL CLONIDINE FOR POST OPERATIVE ANALGESIA IN PATIENTS UNDERGOING LUMBOSACRAL SURGERY
Chairmana et al. Best Practice & Research Clinical Anaesthesiology
Khalil et al. The role of intravenous paracetamol in conscious sedation during Internal Cardioverter Defibrillator (ICD) insertion in geriatric patients
Aronson Drugs that affect autonomic functions or the extrapyramidal system

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220411

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240704

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240903

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240927

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250115

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250115

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250718

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250718

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250919

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250919

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251118

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260109

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260226

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260226